Genital Neoplasms clinical trials at UCSF

4 in progress, 3 open to eligible people

Showing trials for

  • Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

    open to eligible males ages 18 years and up

    The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a). - Part 1 (Monotherapy Dose Escalation): Single-agent VIR-5500 dose escalation - Part 2 (Monotherapy Dose Expansion): Single-agent VIR-5500 dose expansion - Part 3 (Combination Dose Escalation): VIR-5500 plus another therapeutic agent dose escalation Part 3a (Combination Dose Escalation): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI) - Part 4 (Combination Dose Expansion): VIR-5500 plus another therapeutic agent dose expansion Part 4a (Combination Dose Expansion): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI)

    Palo Alto, California and other locations

  • Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    open to eligible females ages 18 years and up

    This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

    San Francisco, California and other locations

  • PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

    open to eligible females ages 18 years and up

    This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.

    San Francisco, California and other locations

  • AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

    Sorry, in progress, not accepting new patients

    This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

    San Francisco, California and other locations

Our lead scientists for Genital Neoplasms research studies include .

Last updated: